Michael S OReilly
Overview
Explore the profile of Michael S OReilly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dudzinski S, Cabanillas M, Hamidi S, Marczyk V, Busaidy N, Dadu R, et al.
J Natl Compr Canc Netw
. 2024 Dec;
23(1.
PMID: 39662038
Background: Definitive radiotherapy (dRT) has been shown to be an effective option for patients with oligometastatic and oligoprogressive cancers; however, this approach has not been well-studied in metastatic thyroid cancer....
2.
Ning M, Odwuor A, Chang J, Gandhi S, Liao Z, Lin S, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518028
Background/objectives: This retrospective study evaluates outcomes of 66 patients who underwent reirradiation (re-RT) with proton beam therapy (PBT) for recurrent non-small cell lung cancer. Methods: Toxicity was scored via the...
3.
Chung C, Khan M, Olanrewaju A, Pham M, Nguyen Q, Patel T, et al.
Radiother Oncol
. 2024 Nov;
202:110609.
PMID: 39486482
Purpose: Radiation treatment planning is highly complex and can have significant inter- and intra-planner inconsistency, as well as variability in planning time and plan quality. Knowledge-based planning (KBP) is a...
4.
Corrigan K, Xu T, Sasaki Y, Lin R, Chen A, Welsh J, et al.
Radiother Oncol
. 2024 Feb;
193:110121.
PMID: 38311031
Introduction: Adjuvant immunotherapy (IO) following concurrent chemotherapy and photon radiation therapy confers an overall survival (OS) benefit for patients with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); however, outcomes...
5.
Lin S, Lin H, Verma V, Xu-Welliver M, Thall P, Yao L, et al.
Cancer Treat Res Commun
. 2022 Jan;
30:100514.
PMID: 35051703
Objective: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung cancer (NSCLC)....
6.
Chang J, Mehran R, Feng L, Verma V, Liao Z, Welsh J, et al.
Lancet Oncol
. 2021 Sep;
22(10):1448-1457.
PMID: 34529930
Background: A previous pooled analysis of the STARS and ROSEL trials showed higher survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early-stage non-small-cell lung cancer (NSCLC), but...
7.
Samson P, Ning M, Shaverdian N, Shepherd A, Gomez D, McGinnis G, et al.
Adv Radiat Oncol
. 2020 May;
5(4):700-704.
PMID: 32395673
No abstract available.
8.
McGinnis G, Ning M, Nitsch P, OReilly M, McAleer M, Koong A, et al.
J Thorac Oncol
. 2020 Apr;
15(6):1085-1087.
PMID: 32311499
No abstract available.
9.
Nguyen Q, Chun S, Chow E, Komaki R, Liao Z, Zacharia R, et al.
JAMA Oncol
. 2019 Apr;
5(6):872-878.
PMID: 31021390
Importance: Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases. Objective: To assess the relative efficacy of high-dose, single-fraction stereotactic body radiotherapy (SBRT)...
10.
Liao Z, Lee J, Komaki R, Gomez D, OReilly M, Fossella F, et al.
J Clin Oncol
. 2018 Jan;
36(18):1813-1822.
PMID: 29293386
Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non-small-cell lung cancer (NSCLC). We hypothesized that...